Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by gregoooon Nov 19, 2012 11:48am

226 Views

Post# 20617664

Citation Resources

In consideration of the sale of QEG, Quetzal will receive US$1,500,000 in cash (plus working capital adjustments) and will also receive a carried interest of 10% on the first two wells drilled by SGS on the QEG properties. Quetzal will also retain an option to participate, by paying its share, in 10% of all other wells drilled by SGS on the QEG properties.

So does SMQ get 10% of the Atzam#4 currently being tested and Atzam#5 which is planned for the near future without any costs? or by the change from SGS to Citation things have changed?

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale